Systemic lupus erythematosus and pregnancy: Before gestation, during and after childbirth
https://doi.org/10.47360/1995-4484-2023-292-297
Abstract
Systemic lupus erythematosus (SLE) is a disease of women of reproductive age. Up to a certain time, pregnancy was contraindicated in patients with SLE, improving the management of the disease itself (monitoring), as well as understanding the safety of drugs make pregnancy possible for most patients with SLE. Careful pregnancy planning is crucial when the disease is well controlled with pregnancy-compatible medications. This is also facilitated by the management of patients jointly by doctors of different specialties (rheumatologist, neurologist, endocrinologist, etc.) with obstetricians. The article discusses the achievements of managing women with SLE during pregnancy planning, during pregnancy and after delivery.
About the Authors
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
N. M. Kosheleva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
References
1. Nasonova VA. Systemic lupus erythematosus. Moscow: Meditsina;1972 (In Russ.).
2. Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412
3. Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):5-14 (In Russ.). doi: 10.14412/1995-4484-2020-5-14
4. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770
5. Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383
6. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi: 10.1002/art.41191
7. Götestam Skorpen C, Hoeltzenbein M, Tincani A, FischerBetz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840
8. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406-414. doi: 10.1016/j.autrev.2018.12.006
9. Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: Clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):39-51. doi: 10.1093/rheumatology/keaa381.
10. Lucas A, Eudy AM, Gladman D, Petri M, Urowitz M, Wyatt CM, et al. The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America. Lupus. 2022;31(11):1401-1407. doi: 10.1177/09612033221123251
11. Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, et al. Belimumab use during pregnancy: A summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2023;82(2):217-225. doi: 10.1136/ard-2022-222505
12. Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford). 2017;56(6):1047-1048. doi: 10.1093/rheumatology/kex039
13. Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, et al. Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. Birth Defects Res. 2023;115(2):188-204. doi: 10.1002/bdr2.2091
14. Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: A case report. Semin Arthritis Rheum. 2014;44(2):195-197. doi: 10.1016/j.semarthrit.2014.05.006
15. Lai Y, Li B, Huang J, Du J, Yue M, Shen X, et al. Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. Lupus. 2023;32(1):149-154. doi: 10.1177/09612033221141805
16. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x
17. Nasonov EL (ed.). Antiphospholipid syndrome. Moscow:Litterra;2004 (In Russ.).
18. Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.). doi: 10.14412/1995-4484-2014-56-71
19. Meroni PL, Borghi MO. Antiphospholipid antibody assays in 2021: Looking for a predictive value in addition to a diagnostic one. Front Immunol. 2021;12:726820. doi: 10.3389/fimmu.2021.726820
20. Reshetnyak TM, Cheldieva FA, Nurbaeva KS, Lila AM, Nasonov EL. Antiphospholipid syndrome: Diagnosis, development, therapy. Thrombosis, Hemostasis and Rheology. 2020;(4):4-21 (In Russ.). doi: 10.25555/THR.2020.4.0940
21. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, SáezComet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry. Eur J Anaesthesiol. 2021;38(9):916-922. doi: 10.1097/EJA.0000000000001484
22. Fredi M, Andreoli L, Bacco B, Bertero T, Bortoluzzi A, Breda S, et al. First report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Front Cardiovasc Med. 2019;6:11. doi: 10.3389/fcvm.2019.00011
23. Costedoat-Chalumeau N, Morel N. Commentary: First report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Front Cardiovasc Med. 2020;7:83. doi: 10.3389/fcvm.2020.00083
24. Vlasova GA, Perminova SG, Kosheleva NM. Approaches to the realization of reproductive function in women with systemic lupus erythematosus and antiphospholipid syndrome. Gynecology. 2021;23(2):167-172 (In Russ.). doi: 10.26442/20795696.2021.2.20073
25. Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Womens Health. 2022;14:199-211. doi: 10.2147/IJWH.S282604
26. Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associations. Lupus. 2002;11(3):175-180. doi: 10.1191/0961203302lu163oa
27. Ma W, Zhan Z, Liang X, Chen J, Huang X, Liao C. Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy. J Womens Health (Larchmt). 2013;22(12):1023-1027. doi: 10.1089/jwh.2013.4255
28. Andreoli L, Fredi M, Nalli C, Reggia R, Lojacono A, Motta M, et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun. 2012;38(2-3):J197-J208. doi: 10.1016/j.jaut.2011.11.010
29. Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the United States: A cross-sectional analysis. Ann Intern Med. 2019;171(3):164-171. doi: 10.7326/M19-0120
30. Alsnes IV, Janszky I, Forman MR, Vatten LJ, Økland I. A population-based study of associations between preeclampsia and later cardiovascular risk factors. Am J Obstet Gynecol. 2014;211(6):1-7. doi: 10.1016/j.ajog.2014.06.026
31. Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33(3):196-205. doi: 10.1053/j.semperi.2009.02.004
32. Nalli C, Manfredi L, Fredi M, Crisafulli F, Bertocchi S, Khizroeva J, et al. Managing puerperium in patients with systemic autoimmune diseases: An update. Expert Rev Clin Immunol. 2022;18(4):391-399. doi: 10.1080/1744666X.2022.2050216
33. Rodríguez Almaraz E, Sáez-Comet L, Casellas M, Delgado P, Ugarte A, Vela-Casasempere P, et al. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. Reumatol Clin (Engl Ed). 2021;17(3):125-131. doi: 10.1016/j.reuma.2019.09.003
34. Delgado P, Robles Á, Martínez López JA, Sáez-Comet L, Rodríguez Almaraz E, Martínez-Sánchez N, et al. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn. Reumatol Clin (Engl Ed). 2021;17(4):183-186. doi: 10.1016/j.reuma.2019.09.004
35. Zhao C, Zhao J, Huang Y, Wang Z, Wang H, Zhang H, et al. New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol. 2013;32(6):815-822. doi: 10.1007/s10067-013-2180-z
36. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060-2068. doi: 10.2215/CJN.00240110
37. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: Risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4): 632-637. doi: 10.1111/j.1538-7836.2008.02921.x
38. Andreoli L, Lazzaroni MG, Carini C, Dall’Ara F, Nalli C, Reggia R, et al. “Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine. 2019;86(4):475-481. doi: 10.1016/j.jbspin.2018.12.002
39. Wolgemuth T, Stransky OM, Chodoff A, Kazmerski TM, Clowse MEB, Birru Talabi M. Exploring the preferences of women regarding sexual and reproductive health care in the context of rheumatology: A qualitative study. Arthritis Care Res (Hoboken). 2021;73(8):1194-1200. doi: 10.1002/acr.24249
40. Carandang K, Mruk V, Ardoin SP, Huynh B, Clowse MEB, Berlan ED, et al. Reproductive health needs of adolescent and young adult women with pediatric rheumatic diseases. Pediatr Rheumatol Online J. 2020;18(1):66. doi: 10.1186/s12969-020-00460-7
41. Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol. 2020;32(3):238-246. doi: 10.1097/BOR.0000000000000710
Review
For citations:
Reshetnyak T.M., Kosheleva N.M., Nasonov E.L. Systemic lupus erythematosus and pregnancy: Before gestation, during and after childbirth. Rheumatology Science and Practice. 2023;61(3):292-297. (In Russ.) https://doi.org/10.47360/1995-4484-2023-292-297
Views:
1100
Email this article 